Provides clinicians with information that can drive treatment decisions in patients with NSCLC.

The Resolution ctDx Lung^TM assay includes actionable genes for targeted FDA-approved therapies
or therapies in clinical trials.

BENEFITS

• An assay that only focuses on genes implicated in lung cancer
• Liquid biopsies can offer a complete picture of tumor heterogeneity
• Useful when tissue biopsies are limited or unobtainable from the patient
• Non-invasive method with testing performed on a blood sample
• Faster turn-around time compared to tissue NGS profiling¹
• Covered by Medicare, all Medicare Advantage plans, Aetna, UnitedHealthcare, Cigna and other regional health plans

CLINICAL RESPONSE DATA

In a prospective clinical study, the Resolution ctDx Lung assay demonstrated the following performance¹:

• Somatic mutations detected in 64% (135/210) of patients

• 97% (34/35) of patients who received plasma-directed therapy had a clinical and radiological response to the matched targeted therapy

• 46% (96/210) of patients had an oncogenic driver alteration detected, including actionable mutations in EGFR, ALK, MET, BRAF, ROS1, and RET

• 90% (60/67) positive concordance between plasma and tissue NGS testing. Sub-analysis demonstrated

• 96% (49/51) positive concordance within NCCN® oncogenic recognized driver alterations in lung cancer.

GENE LIST
The Resolution ctDx Lung™ assay targets actionable, somatic SNVs, indels,
fusions, and copy number variants in 22 genes in NSCLC.²

Please see the test menu for additional specimen and test information.

References

1. Sabari, J. et al. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers; JNCI J Natl Cancer Inst 2019 111(6) djy156.

2. Resolution Bioscience, Inc. ctDx Lung Panel. http://www.resolutionbio.com/assays/nsclc.html. Accessed March 9, 2020.